Nicolas Larmonier, Ph.D.
Professor, Immunology
Head, Group « Oncoimmunology and cancer immunotherapy »
CNRS UMR 5164 / UF Biology - University of Bordeaux

Campus Carreire, Zone Nord, Bât. 1B RdC 08
146 rue Léo Saignat,
33076 Bordeaux cedex, France

Phone: 05 57 57 92 75
nicolas.larmonier@u-bordeaux.fr

Fields of research and expertise

Cancer immunology and immunotherapy
Mechanisms of immunosuppression, regulatory T lymphocytes, myeloid-derived suppressor cells (MDSC), role and plasticity of Th17, Th9, Treg in cancers

Education and Academic Degrees

2000 **M.S., Biochemistry, Molecular and Cellular biology**
Faculty of Medicine, University of Burgundy, Dijon, France

2004 **Ph.D. in Biochemistry, Molecular and Cellular biology, Cancer immunology**
Faculty of Medicine, University of Burgundy, Dijon, France

2008 **Accreditation to Direct Research (HDR)**
University of Burgundy, Dijon, France

Post-Doctoral Training

2004-2006 **Post-Doctoral Research Associate**
Steele Children's Research Center, Oncology/Hematology Section
University of Arizona, Tucson, AZ, USA

Academic/Faculty Appointments

2006-2009 **Research Assistant Professor**
Steele Children's Research Center / Department of Pediatrics,
University of Arizona, Tucson, AZ, USA

2007-2009 **Research Assistant Professor (Joint-Appointment)**
Department of Immunobiology
University of Arizona, Tucson, AZ, USA

2007-2015 **Member, BIO5 Research Institute and Arizona Cancer Center**
University of Arizona, Tucson, AZ, USA

2009-2015 A**ssociate Professor (Research Scholar Track)**
Pediatrics and Immunobiology
University of Arizona, Tucson, AZ, USA

Director, Oncology/Hematology Research
Steele Children's Research Center
University of Arizona, Tucson, AZ, USA

2015- **Professor (PR), Immunology (Section CNU 65, Immunology)**
UF Biology / CNRS UMR5164
University of Bordeaux, Bordeaux, France

Teaching and Mentoring activities

University of Burgundy:

2000-2003 **Lectures in Cellular Biology** (192 hr; 64 hr/yr)
Instructorship, Centre d'Initiation à l'Enseignement Supérieur, Ecole Normale Supérieure, Lyon, France
First and second year students in life science (Biology), University of Burgundy, France

University of Arizona:

♦ Teaching:

2006-2008 **Immunobiology Course -IMB 562, Tumor Immunology**
«Tolerance and regulatory T lymphocytes» Two lectures (5 hr/yr)
Immunobiology Graduate Program, University of Arizona, Tucson, AZ, USA

2008 **Immunobiology Course -IMB 560A, Development of the Immune System**
Class Co-Director. Ten lectures (20 hr)
Immunobiology Graduate Program, University of Arizona, Tucson, AZ, USA

2009-2011 **Cancer Biology Course -CBIO 555, Cancer Therapeutics**
«Cancer Immunotherapy» Two lectures (3 hr/yr)
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

2010-2015 **Cancer Biology Course -CBIO 567, Cancer Immunology and Immunotherapy**
Class Director. Creation and development of the Course. Thirty lectures (50 hr/yr).
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

2011-2015 **Immunobiology Course -IMB 564, Advanced Topics in Immunology**
«Tumor Immunology, Immunotherapy» Two lectures (3 hr/yr)
Immunobiology Graduate Program, University of Arizona, Tucson, AZ, USA USA

2011-2015 **Cancer Biology Course -CBIO 552, Cancer Biology**
«Mechanisms of tumor escape from the immune system – Inflammation -induced cancer» (4 hr/yr)
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

2012-2015 **Cancer Biology Course -CBIO 553, Advanced Topics in Cancer Biology**
«Tumor vaccines: promises and challenges» Analysis and discussion of scientific articles (4 hr/yr)
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

2012-2015 **Cancer Biology -CBIO 595C, Colloquium**
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA
Director. (~20 hr/yr)

2013-2015 **Cancer Biology -CBIO 561, Clinical Cancer Biology**
«Tumor Immunology and Immunotherapy of Cancers» (1 hr)
Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

♦ Faculty Member in Graduate Programs (Master and Ph.D. level):

2007-2015 **Immunobiology Graduate Program Faculty**
University of Arizona, Tucson, AZ, USA

2008-2015 **Cancer Biology Graduate Interdisciplinary Program Faculty**
University of Arizona, Tucson, AZ, USA

♦ Faculty Advisor:

2008-2015 **Biochemistry, Molecular and Cellular Biology –BIOC 399H and 499H, Honors Thesis**
University of Arizona, Tucson, AZ, USA

2008-2015 **Surgery/Medicine 800A -Research Distinction Track, Medical Research Program**
University of Arizona, Tucson, AZ, USA

2010-2015 **Undergraduate Biology Research Program (UBRP)**
University of Arizona, Tucson, AZ, USA

2012-2015 **Undergraduate Research Opportunity Consortium (UROC)**
University of Arizona, Tucson, AZ, USA

2014-2015 **NAP-UBRP Undergraduate Research Opportunity Consortium (UROC)**
University of Arizona, Tucson, AZ, USA

♦ Mentor/Thesis Director:

Postdoctoral Research Associates:

2007-2010 Nona Janikashvili, Ph.D.
Steele Children's Research Center, Department of Pediatrics
University of Arizona, Tucson, AZ, USA

2011-2012 Collin LaCasse, Ph.D.
NIH T32 Cancer Biology Post-Doctoral Training Grant
University of Arizona, Tucson, AZ, USA

Medical Residents:

2009-2011 Raquel Bravo, M.D.
Steele Children's Research Center, Department of Pediatrics
University of Arizona, Tucson, AZ, USA

Graduate level (Ph.D. degree):

2005-2009 Jessica Cantrell, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA
Thesis dissertation: "*Adjuvant effects of Chaperone Rich Cell Lysate: the effects of CRCL on the activation of immune cells*". Defended 03/10/2009

2007-2011 Collin LaCasse, Immunobiology Graduate Program
University of Arizona, Tucson, AZ, USA
Thesis dissertation: "*Negative modulation of regulatory T cells and promotion of the tumoricidal activity of dendritic cells in cancer: a double edged strategy*". Defended 04/22/2011

2007-2011 Jennifer Fraszczak, Biochemistry, Molecular and Cellular Biology Graduate Program
University of Burgundy, Dijon, France
Thesis dissertation: "*Les cellules dendritiques cytotoxiques: outils en immunotherapy anti-tumorale*".
Defended 05/20/2011

2008-2011 Sara Bustamante, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA
Thesis dissertation: "*Negative regulation of regulatory T cells by myeloid-derived suppressor cells in cancer*". Defended 04/12/2011

2009-2012 Neale Hanke, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA
Thesis dissertation: "*Molecular regulation of the tumor killing activity of dendritic cells*".
Defended 11/14/2011

2008-2012 Malika Trad, Biochemistry, Molecular and Cellular Biology Graduate Program
University of Burgundy, Dijon, France
Thesis dissertation: "*Implication des cellules d'origine myéloide dans l'inhibition de la réponse immunitaire anti-tumorale*". Defended 12/11/2012

2010-2013 Darya Alizadeh, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA
Thesis dissertation: "*Doxorubicin and T helper lymphocytes: unexpected allies against cancer*". Defended 11/08/2013

2012-2015 Martin Asimis (MS Degree), Molecular and Cellular Biology Graduate Program
University of Arizona, Tucson, AZ, USA

Medical Students:

2008-2012 Jason Wright, Medical Student Research Fellowship
Research Distinction Track, Surgery/Interdepartmental Medicine 800A
University of Arizona, Tucson, AZ, USA

2009-2012 Elaine Situ, Medical Student Research Fellowship
Research Distinction Track, Surgery/Interdepartmental Medicine 800A
University of Arizona, Tucson, AZ, USA

2010 Andres Langoria, Second Year Medical Student
University of Arizona, Tucson, AZ, Tucson

06-08/2013 Elaine Hutchinson, Second Year Medical Student
Medical Research Program
University of Arizona

Undergraduate level:

2007-2009 Elaine Situ, Molecular and Cellular Biology Department (Senior Honors Thesis: *"Evaluation of Tumor Necrosis Factor-Related Apoptosis-Inducting Ligand (TRAIL) effects on Regulatory T cells"*)
University of Arizona, Tucson, AZ, USA

2008 Amanda Herrell, Microbiology Department (Senior Honors Thesis: *"Tumor-Derived Chaperone Rich Cell Lysate (CRCL): Optimization for Cancer Immunotherapy"*)
University of Arizona, Tucson, AZ, USA

2010-2011 Leila Amini, Biochemistry and Molecular Biophysics Department (Senior Honors Thesis: *"Differential Regulation of iNOS-Dependent Tumor Cell Killing by Dendritic Cells Generated With IL-4 or IL-15"*)
Undergraduate Biology Research Program
University of Arizona, Tucson, AZ, USA

2011 Michael Seacat, Physiology Department
University of Arizona, Tucson, AZ, USA

2012-2014 Jessica Stokes, Chemistry and Biochemistry
University of Arizona, Tucson, AZ, USA

2012-2014 Evangelia Assimacopoulos, Molecular and Cellular Biology
University of Arizona, Tucson, AZ, USA

Graduate Level Training (laboratory rotations):

Spring 2008 Marc Teng, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

Spring 2008 Sara Bustamante, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

Spring 2008 Rajalakshmy Ramalingam, Immunobiology Graduate Program
University of Arizona, Tucson, AZ, USA

Spring 2009 Neale Hanke, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

Fall 2010 Alexis Bucknam, Immunobiology Graduate Program
University of Arizona, Tucson, AZ, USA

Other trainings and visiting students:

07-09/2006 Delphine Mérino, Graduate Student
Biochemistry, Cellular and Molecular Biology Graduate Program
Visiting Student (University of Burgundy) at the University of Arizona

04-06/2009 Sophie Marin, University Institutes of Technology (IUT) Second Year Student
Biochemical and Biological Analysis
IUT Nancy-Brabois, France

05-08/2009 Bradley Bowman, Minority Research Training Program
University of Arizona

04-06/2010 Anthony Piluti, University Institutes of Technology (IUT) Second Year Student
Biochemical and Biological Analysis
IUT Nancy-Brabois, France

04-06/2011 Juliette Ambrosini, University Institutes of Technology (IUT) Second Year Student
Biochemical and Biological Analysis
IUT Nancy-Brabois, France

04-06/2012 Lucas Barthly, University Institutes of Technology (IUT) Second Year Student
Biochemical and Biological Analysis
IUT Nancy-Brabois, France

06-08/2012 Edwin Nieblas, Undergraduate Minority Health Disparities Summer Research Program
Undergraduate Research Opportunities Consortium
University of Arizona

06-08/2012 Nageena Khalid, Summer Institute of Medical Ignorance Research Program
University of Arizona

06-08/2012 Maria Fernanda Acosta, Universidad La Salle, Mexico City
Undergraduate Research Opportunities Consortium
Latin American Summer Research Program in the University of Arizona

Research Specialists/Technicians:

2008-2009 Tamara Lundeen, MS. Research Specialist, Department of Pediatrics
University of Arizona, Tucson, AZ, USA

2009-2010 Amanda Herrell, Research Technician, Department of Pediatrics
University of Arizona, Tucson, AZ, USA

2010-2011 Jessica Kartchner, Research Technician, Department of Pediatrics
University of Arizona, Tucson, AZ, USA

High School Students:

07/2010 Sammy Kagnan, University High School Student
8/10-7/10 Alexandra Prassas, Ironwood Ridge High School Student
6/11-7/11 Nageena Khalid, 2011 NIH Disadvantaged High School Student Research Program
2/12-5/12 Ariana Katsanis, Catalina Foothills High School, Tucson, AZ

♦ Graduate Student Committees:

2007-2009 Jessica Cantrell (Ph.D. degree), Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

2008-2009 Maria Ordaz (Ph.D. degree), Immunobiology Graduate Program
University of Arizona, AZ, USA

2007-2011 Collin LaCasse (Ph.D. degree), Immunobiology Graduate Program
University of Arizona, Tucson, AZ, USA

2008-2011 Sara Bustamante, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

2009-2012 Neale Hanke, Cancer Biology Graduate Interdisciplinary Program (Chair)
University of Arizona, Tucson, AZ, USA

2011-2012 Diane Gabsert (Master degree), Medical Pharmacology Graduate Program
University of Arizona, Tucson, AZ, USA

2011-2013 Supannikar Tawinwung (Ph.D. degree), Medical Pharmacology Graduate Program
University of Arizona, Tucson, AZ, USA

2011-2013 Darya Alizadeh, Cancer Biology Graduate Interdisciplinary Program (Chair)
University of Arizona, Tucson, AZ, USA

2012-2014 Candida Bhagwandin (Ph. D. degree), Cellular and Molecular Medicine Graduate Program
University of Arizona, Tucson, AZ, USA

2012-2014 Beenish Atiya Majeed (Ph.D. degree), Medical Pharmacology Graduate Program
University of Arizona, Tucson, AZ, USA

2013-2014 Max Conrad Lowther (Master degree), Cellular and Molecular Biology Graduate Program
University of Arizona, Tucson, AZ, USA

2015 Adam Watson, Cancer Biology Graduate Interdisciplinary Program
University of Arizona, Tucson, AZ, USA

University of Bordeaux:

♦ Teaching:

2016- **Cellular, molecular and adaptive immunity (course director)**
Master Biology-Health, Specialty Microbiology-Immunology M2R

2016- **Protective and pathologic immunity**
Master Biology-Health, M1

2015- **Immunobiology, advanced Immunology (course director)**
Master Biology-Health, Specialty Microbiology-Immunology M1

2015- **Communication et conception d'un projet de recherche/développement (KM3MR03U)**
Master Biologie-Santé, Spécialité Microbiologie-Immunologie M2 Recherche

♦ Mentor:

Master M1 and M2

09/16-09/17 Céline Blaye, Master 2R Biologie-Santé, Spécialité Cancérologie, Faculté de Médecine Paris Sud, Institut Gustave Roussy

09/16-06/17 Andrea Boizard-Moracchini, Master 2R Biologie Santé, Spécialité Microbiologie-Immunologie, Université de Bordeaux

04-05/2016 Andrea Boizard-Moracchini, Master 1 Biologie Santé, Spécialité Microbiologie-Immunologie, Université de Bordeaux

♦ Ph.D Thesis commitees:

2015 Alexandrine Gautheron (Dijon) (reviewer)

Grant Reviewer

2010 Congressionally Directed Medical Research Program (CDMRP), US Department of Defense
2010 Peer Reviewed Cancer Research Program - Blood Cancers-Listeria Vaccine-Radiation, BC-LV-RP Study Section, Washington DC.
Panel Scientist Reviewer.

2012 Cancer Research UK - Career Development Program

2013 Association for International Cancer Research

2014 Congressionally Directed Medical Research Program (CDMRP), US Department of Defense
2013 Breast Cancer Research Program Immunology-3 (IMM-3) Peer Review Panel, Washington DC.
Scientist Reviewer.

2014 Belgian Foundation against Cancer

Journal Reviewer (*ad hoc* reviewer)

Archivum Immunologiae et Therapiae Experimentalis
Biochimica et Biophysica Acta – General Subjects
Biology of Blood and Marrow Transplantation
Blood
Cancer Research
Cancer Immunology Immunotherapy
Clinical Medicine: Oncology
Expert Review of Anticancer Therapy
Frontiers in Immunology, Alloimmunity and Transplantation
Haematological- The Hematology Journal
Immunobiology
Immunotherapy
International Journal of Cancer
Journal of Leukocyte Biology
Leukemia
Molecular Cancer Therapeutics
Nature Medicine
PlosONE
Vaccine

Journal Editorial Board

2011- American Journal of Blood Research
2012- Journal of Vaccines
2014- Frontiers in Tumor Immunology
2014 Guess Editor, BioMed Research International, Special Issue on T Lymphocyte Plasticity in Autoimmunity and Cancer

Membership in professional organizations

2001-2004 Club Francophone des Cellules Dendritiques
2006- American Association for Cancer Research
2012- American Association of Immunologist
2012- Society of Leukocyte Biology

Honors and Awards

2000-2003 MENRT doctoral grant**, French Ministry of National Education, Research and Technology**
Instructorship funding, **French Ministry of National Education, Research and Technology**

2003-2004 Doctoral funding, **French National League against Cancer**

2006 Two-year Fellowship Award, **Lymphoma Research Foundation** ($ 105,000)
Declined 4-10-2006 due to funding from the Leukemia and Lymphoma Society

2006-2009 Career Development Fellow Award, **Leukemia and Lymphoma Society**
Grant # 5188-07

2009 Outstanding Honors Faculty Member Award 2008-2009, **University of Arizona Honors College**

2010 Vernon and Virginia Furrow Award for Excellence in Graduate Student Education -2010, **University of Arizona**

Other academic/administrative responsibilities

University of Arizona

2008-2009 Interviewer, Department of Surgery search committee for Faculty candidates
University of Arizona, Tucson, Arizona, USA

2008-2011 Interviewer/Evaluator, PhD student candidates, Immunobiology and Cancer Biology Graduate Programs
University of Arizona, Tucson, Arizona, USA

2008-2010 Interviewer, College of Medicine Medical Student Admission
University of Arizona, Tucson, Arizona, USA

2008-2010 Faculty Advisor, The University of Arizona March of Dimes Collegiate Council
University of Arizona, Tucson, Arizona, USA

2009-2015 Member, Department of Pediatrics space committee
University of Arizona, Tucson, Arizona, USA

2009-2015 Interviewer, Department of Immunology search committee for Faculty candidates
University of Arizona, Tucson, Arizona, USA

2011-2015 Interviewer/Evaluator, Arizona Biological and Biomedical Sciences Program, PhD student candidates
University of Arizona, Tucson, Arizona, USA

Université de Bordeaux:

2015 Membre, Comité Scientifique des Translationnelles en Immuno-Oncologie du Cancéropôle Grand Sud-Ouest

Bibliography (http://www.ncbi.nlm.nih.gov/pubmed/?term=Larmonier+N)

♦ Primary research articles

1) T.P. Twaroski, M.L. O' Brien, **N. Larmonier**, H.P. Glauert, and L.W. Robertson. Polychlorinated biphenyl (PCB)-induced effects on metabolic enzymes, AP-1 binding, vitamin E and oxidative stress in the rat liver. **Toxicology and Applied Pharmacology**. 171: 85-93. 2001.

2) S. Gurbuxani, J.M. Bruey, A. Fromentin, **N. Larmonier**, A. Parcellier, M. Jaattela, F. Martin, E. Solary, and C. Garrido. Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. **Oncogene**. 20: 7478-7485. 2001.

3) B. Bonnotte, **N. Larmonier**, N. Favre, A. Fromentin, M. Moutet, M. Martin, S. Gurbuxani, E. Solary, B. Chauffert, and F. Martin. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. **The Journal of Immunology**. 167: 5077-5083. 2001.

4) **N. Larmonier**, C. Billerey, C. Rébé, A. Parcellier, M. Moutet, A. Fromentin, G. Kroemer, C. Garrido, E Solary, F. Martin and B. Bonnotte. An atypical caspase-independent death pathway for an immunogenic cancer cell line. **Oncogene**. 21: 6091-6100. 2002.

5) J.G. Fischer, H.G. Glauert, T. Yin, M.L. Sweeney-Reeves, **N. Larmonier**, and M.C. Black. Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-kappaB activation induced by the peroxisome proliferator, Wy-14,643. **The Journal of Nutrition**. 9: 2525-2531. 2002.

6) **N. Larmonier**, F. Ghiringhelli, C.B. Larmonier, M. Moutet, A. Fromentin, E. Baulot, E. Solary, B. Bonnotte, and F. Martin. Freshly isolated bone marrow cells induce death of various carcinoma cell lines. **International Journal of Cancer.** 107: 747-756. 2003.

7) C.B. Larmonier/L. Arnould, **N. Larmonier**, S. Baumann , M. Moutet, V. Saint-Giorgio, A. Pance, and J.F. Jeannin. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. **International Journal of Molecular Medicine**. 13: 355-361. 2004.

8) F. Ghiringhelli*/**N. Larmonier***, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. $CD4^+CD25^+$ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. **European Journal of Immunology**. 34: 336-344. 2004. **(* Co-first author)**

9) B. Bonnotte, M. Crittenden, **N. Larmonier,** M. Gough, and R.G. Vile. MIP-3α transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. **The Journal of Immunology.** 173: 4929-4935. 2004.

10) X. Chen, Y. Zeng, G. Li, **N. Larmonier**, M.W. Graner, and E. Katsanis. Peritransplantation vaccination with chaperone rich cell lysate induces antileukemia immunity. **Biology of Blood and Marrow Transplantation**. 12: 275-283. 2006.

11) Y. Zeng, X. Chen, **N. Larmonier**, C. Larmonier, G. Li, M. Sepassi, M. Marron, S. Andreansky, and E. Katsanis. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. **International Journal of Cancer**. 119: 2624-2631. 2006.

12) **N. Larmonier,** D. Mérino, A. Nicolas, D. Cathelin, A. Besson, A. Bateman, E. Solary, F. Martin, E. Katsanis, and B. Bonnotte. Apoptotic, necrotic or fused tumor cells: an equivalent source of antigen for dendritic cell loading. **Apoptosis**. 11: 1513-1524. 2006.

13) **N. Larmonier**, M. Marron, Y. Zeng, J. Cantrell, A. Romanoski, M. Sepassi, S. Thompson, X. Chen, S. Andreansky, and E. Katsanis. Tumor-derived $CD4^+CD25^+$ regulatory T cells suppression of dendritic cell function involves TGF-β and IL-10. **Cancer Immunology and Immunotherapy**. 56: 48-59. 2007.

14) X. Chen, B. Zhou, M. Li, Q. Deng, X. Wu, X. Le, C. Wu, **N. Larmonier**, W. Zhang, H. Zhang, H. Wang, and E. Katsanis. $CD4^+CD25^+FoxP3^+$ regulatory T cells suppress *Mycobacterium tuberculosis* immunity in patients with active disease. **Clinical Immunology**, 123: 50-59. 2007.

15) G. Li, Y. Zeng, X. Chen, **N. Larmonier**, M. Sepassi, M.W. Graner, S. Andreansky, M.A. Brewer and E. Katsanis. Human ovarian tumor-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. **Clinical and Experimental Immunology**, 148: 136-145. 2007.

16) **N. Larmonier**, D. Cathelin, C. Larmonier, A. Nicolas, D. Merino, N. Janikashvili, S. Audia, A. Bateman, J. Thompson, T. Kottke, T. Hartung, E. Katsanis, R. Vile, and B. Bonnotte. The inhibition of TNF-α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. **Experimental Cell Research**, 313: 2345-2355. 2007.

17) A. Nicolas/D. Cathelin, **N. Larmonier**, J. Fraszczak, P.E. Puig, A. Bouchot, A. Bateman, E. Solary, and B. Bonnotte. Dendritic cells trigger tumor cell death by a nitric oxide -dependent mechanism. **The Journal of Immunology**, 179: 812-818. 2007.

18) S. Audia/A. Nicolas, D. Cathelin, **N. Larmonier**, C. Ferrand, P. Foucher, A. Fanton, E. Bergoin, M. Maynadie, L. Arnould,, A. Bateman, Lorcerie, B., E. Solary, B. Chauffert, and B. Bonnotte. Increase of $CD4^+CD25^+FoxP3^+$ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate $CD4^+CD25^+FoxP3^+$ T lymphocytes. **Clinical and Experimental Immunology**, 150: 523-530. 2007.

19) G. Li, S. Andreansky, G. Helguera, M. Sepassi, N. Janikashvili, J. Cantrell, C.L. LaCasse, **N**. **Larmonier**, M.L. Penichet, and E. Katsanis. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. **Molecular Cancer Therapeutics**, 7: 721-729. 2008.

20) **N. Larmonier**, J. Cantrell, C. LaCasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky and E. Katsanis. Chaperone-rich tumor cell lysate -mediated activation of antigen presenting cell resists regulatory T cell suppression. **Journal of Leukocyte Biology**, 83: 1049-1059. 2008.

21) C. Billerey-Larmonier, J.K. Uno, **N. Larmonier**, A.J. Midura, B. Timmermann, F.K. Ghishan, and P.R. Kiela. Protective effects of dietary curcumin in mouse model of chemically-induced colitis are strain dependent. **Inflammatory Bowel Diseases**, 14: 780-793. 2008.

22) **N. Larmonier***, N. Janikashvili, C. J. LaCasse, C. Larmonier, J. Cantrell, E. Situ, T. Lundeen, B. Bonnotte and E. Katsanis. Imatinib mesylate inhibits $CD4^+CD25^+$ regulatory T cell activity and enhances active immunotherapy against $BCR\text{-}ABL^{negative}$ tumors. **The Journal of Immunology.** 181: 6955-6963. 2008. (* Corresponding author)

23) X. Chen, M. Zhang, X. Zhu, Q. Deng, H. Liu, **N. Larmonier**, M.W. Graner and B. Zhou. Engagement of Toll-Like Receptor 2 on $CD4^+$ T cells facilitates local immune responses in patients with tuberculous pleurisy. **The Journal of Infectious Diseases**. 200: 399-408. 2009.

24) X. Chen, Q. Yang, M. Zhang, M. Graner, X. Zhu, **N. Larmonier**, M. Liao, W. Yu, Q. Deng, B. Zhou. Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay. **Clinical and Vaccine Immunology**. 16: 879-884. 2009.

25) J. Cantrell, C. Larmonier, N. Janikashvili, S. Bustamante, J. Fraszczak, A. Herrell, T. Lundeen, C. J. LaCasse, E. Situ, **N. Larmonier*** and E. Katsanis*. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. **Immunobiology**. 215: 534-544. 2010. **(* Co-senior authorship).**

26) J. Fraszczak, M. Trad, N. Janikashvili, D. Cathelin, D. Lakomy, V. Granci, A. Morizot, S. Audia, O. Micheau, L. Lagrost, E. Katsanis, E. Solary, **N. Larmonier*** and B. Bonnotte*. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. **The Journal of Immunology**. 184: 1876-1884. 2010. **(* Co-senior authorship)**

27) M. Ordaz, **N. Larmonier** and L. Lybarger. DC-expressed MHC Class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens. **Cellular Immunology**. 262: 141-149. 2010.

28) C.B. Larmonier, M.T. Midura-Kiela, , R. Ramalingam, D. Laubitz, N. Janikashvili, **N. Larmonier**, F.K. Ghishan and P.R. Kiela. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. **Inflammatory Bowel Diseases**. 17: 503-515. 2011.

29) N. Janikashvili/C.J. LaCasse, M. Trad, A. Herrell, S. Bustamante, M. Har-Noy, **N. Larmonier*** and E. Katsanis***.** Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. **Blood.** 117: 1555-1564. 2011. **(* Co-senior authorship)**

30) D. Lakomy/N. Janikashvili, J. Fraszczak, M. Trad, S. Audia, M. Samson, M. Ciudad, J. Vinit, C. Vergely, D. Caillot, P. Foucher, L. Lagrost, S. Chouaib, E. Katsanis, **N. Larmonier*** and B. Bonnotte*. Cytotoxic dendritic cells generated from cancer patients. **The Journal of Immunology.** 187: 2775-2782. 2011. **(* Co-senior authorship)**

31) S. Audia, M. Samson, J. Guy, N. Janikashvili, J. Fraszczak, M. Trad, M. Ciudad, V. Leguy, S. Berthier, T. Petrella, S. Aho-Glélé, L. Martin, M. Maynadié, B. Lorcerie, P. Rat, N. Cheynel, E. Katsanis, **N. Larmonier** and B. Bonnotte. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. **Blood.** 118: 4394-4400. 2011.

32) C.J. LaCasse, N. Janikashvilli, C.B. Larmonier, D. Alizadeh, N.T. Hanke, J. Kartchner, E. Situ, S. Centuori, M. Harnoy, B. Bonnotte, E. Katsanis and **N. Larmonier**. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFNγ-dependent mechanism. **The Journal of Immunology.** 187: 6310-6317. 2011.

33) M. Samson, S. Audia , J. Fraszczak, M. Trad , P. Ornetti , D. Lakomy , M. Ciudad, V. Leguy, S. Berthier, J. Vinit, P. Manckoundia, J.F. Maillefert , J.F. Besancenot, S. Aho-Glele, O.N. Olsson , B. Lorcerie, L. Guillevin, L. Mouthon, P. Saas, A. Bateman, L. Martin, N. Janikashvili, **N. Larmonier** and B. Bonnotte. Th-1 and Th-17 lymphocytes expressing CD161 are implicated in Giant Cell Arteritis and Polymyalgia Rheumatica pathogenesis. **Arthritis and Rheumatism**. 64: 3788-3798. 2012.

34) S. Centuori, M. Trad, C.J. LaCasse, D. Alizadeh, C. B. Larmonier, N.T. Hanke, J. Kartchner, N. Janikashvili, Bonnotte, **N. Larmonier*** and E. Katsanis*. Tumor-induced myeloid-derived suppressor cells impair the differentiation of $CD4^+CD25^+FoxP3^+$ regulatory T cells from naïve $CD4^+CD25^-FoxP3^-$ T lymphocytes. **Journal of Leukocyte Biology**. 92: 987-997. 2012. **(* Co-senior authorship)**.

35) S. Audia, M. Samson, M. Mahévas, C. Ferrand, M. Trad, M. Ciudad, A. Gautheron, F. Seaphanh, V. Leguy-Seguin, S. Berthier, B. Salles, L. Martin, B. Lorcerie, P. Ortega-Deballon, O. Facy, D. Caillot, A. Soudry-Faure, M. Michel, B. Godeau, **N. Larmonier**, P. Saas, N. Janikashvili and B. Bonnotte. Preferential splenic $CD8^+$ T cell activation in rituximab-non responder patients with immune thrombocytopenia. **Blood**. 122:2477-86. 2013

36) D. Alizadeh, M. Trad, N. Hanke, C. B. Larmonier, N. Janikashvili, B. Bonnotte, E. Katsanis and **N. Larmonier**. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer. **Cancer Research**, 74(1): 104-118. 2014.

37) N.T. Hanke/C.J. LaCasse, C. Larmonier, D. Alizadeh, M. Trad, B. Bonnotte, N. Janikashvili, E. Katsanis and **N. Larmonier**. PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15. **European Journal of Immunology**, 44(8):2489-2499. 2014.

38) B. Majeed, S. Tawinwung, L.S. Eberson, T.W. Secomb, **N. Larmonier** and D.F. Larson. Interleukin-2/Anti-Interleukin-2 Immune Complex Expands Regulatory T Cells and Reduces Angiotensin II-Induced Aortic Stiffening. International Journal of Hypertension. 2014:126365. 2014.

39) N. Janikashvili, M. Trad, A. Gautheron, M. Samson, B. Lamarthee, F. Bonnefoy, M. Ciudad, F. Seaphanh, B. Gaugler, S. Perruche, A. Bateman, L. Martin, S Audia, P. Saas, **N. Larmonier*** and Bernard Bonnotte*. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory FoxP3+CD8+ T lymphocytes. **Journal of Allergy and Clinical Immunology**,135(6):1614-1624e4. 2015. **(* Co-senior authorship)**.

40) B.A. Majeed, L.S. Eberson, S. Tawinwung, **N. Larmonier**, T.W. Secomb, and D.F. Larson. Functional aortic stiffness: role of $CD4^+$ T lymphocytes. **Frontiers in Physiology**, 6 :235. DOI : 10.3389/fphys.2015.00235. 2015.

41) J. Stokes, E.A. Hoffman, Y. Zeng, **N. Larmonier** and E. Katsanis. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrrow transplantation. **British Journal of Haematology**. 174(1):102-116. 2016.

♦ Review articles, book chapters and commentaries

1) **N. Larmonier**, J. Fraszczak, D. Lakomy, B. Bonnotte and E. Katsanis. Killer dendritic cells and their potential for cancer immunotherapy. **Cancer Immunology Immunotherapy**. 59: 1-11. 2010. Review.

2) N. Janikashvili, **N. Larmonier** and E. Katsanis. Personalized dendritic cell-based tumor immunotherapy. **Immunotherapy**. 2 : 57-68. 2010. Review.

3) N. Janikasvili, B. Bonnotte, E. Katsanis and **N. Larmonier**. The dendritic cell-regulatory T lymphocyte cross-talk contributes to tumor-induced tolerance. **Clinical and Developmental Immunology.** 2011: 430394, 1-14. Review.

4) **N. Larmonier**, B. Bonnotte, E. Katsanis. Cytotoxic and antigen presenting function of T helper-1-activated dendritic cells. **OncoImmunology.** 1 (4) : 566-568. 2012. Invited commentary.

5) E. Katsanis and **N. Larmonier**. Combining cancer vaccines and T lymphocyte modulation. **World Hellenic Biomedical News.** 3 (1) : 10-14. 2012. Review.

6) **N. Larmonier** and E. Katsanis. Dendritic Cells for Cancer Immunotherapy. In **Emerging Trends in Cell and Gene Therapy.** Springer Science, New York / Heidelberg. Chap. 11. 251-270 (Book Chapter).

7) N.T. Hanke, D. Alizadeh, E. Katsanis and **N. Larmonier**. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. **Critical Reviews in Immunology**. 33 (1) 1-21. 2013. Review

8) D. Alizadeh, E. Katsanis and **N. Larmonier**. Chemotherapeutic targeting of myeloid-derived suppressor cells. **OncoImmunology.** 3:e27359. 2014. Invited commentary.

9) D. Alizadeh, E. Katsanis and **N. Larmonier**. The multifaceted role of Th-17 lymphocytes and their associated cytokines in cancer. **Clinical and Developmental Immunology**. 2013: 957878, 1-11. 2013. Review.

10) D. Alizadeh and **N. Larmonier**. Chemotherapeutic targeting of immunosuppressive cells in cancer. **Cancer Research,** 74(10): 2663-2668. 2014. Review.

11) N. Janikashvvili, T. Chikovani, S. Audia, B.Bonnotte and **N. Larmonier.** T lymphocyte plasticity in autoimmunity and cancer. **BioMed Research International**. 2015:540750. Editorial

12) D. Alizadeh and **N. Larmonier**. Generation and expansion of T helper17 lymphocytes *ex vivo*. **Methods in molecular biology** (Clifton, N.J.). 1371: 101-113. 2016.

♦ Abstracts

Fischer, J., H.P. Glauert, M. Black, **N. Larmonier**, M. Sweeney, and T. Yin. High iron intake does not enhance activation of hepatic NF-κB by Wy-14, 643, a peroxisome proliferator. Experimental Biology 99, Washington DC, 1999. **FASEB J. 13: A917**.

Twaroski, T.P., **N. Larmonier,** M.L. O'Brien, H.P. Glauert, and L.W. Robertson. PCB-induced effects on cytochrome P-450 1A1, DT-Diaphorase, AP-1 binding and oxidative stress in the rat liver. Molecular Carcinogenesis. 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000. **Proceedings of the American Association for Cancer Research**. **41: 507**.

C.B. Larmonier, J.K. Uno, M.A. Lipko, **N. Larmonier**, F. Ghishan, and P.R. Kiela. Protective effects of dietary curcumin in trinitrobenzene sulfonic acid (TNBS)-induced colitis are mouse strain-dependent. **Gastroenterology. 132 (4): A229-A229 Suppl. 2. 2007**.

J. Wright, E. Katsanis, and **N. Larmonier**. Modulation of regulatory T lymphocytes by killer dendritic cells. **Journal of Investigative Medicine. 57: 97. 2009**. *Best Abstract, EE Osgood Award from the Western Society of Clinical Investigation.*

J. Wright, **N. Larmonier**, and E. Katsanis. Conversion inhibition of naïve T lymphocytes into regulatory T cells by killer dendritic cells. **Journal of Investigative Medicine. 58: 216. 2010**.

E. Situ, E. Katsanis, and **N. Larmonier.** Influence of Imatinib Mesylate on bone marrow-derived dendritic cells. **Journal of Investigative Medicine. 58: 91. 2010**.

D. Alizadeh, M. Trad, E. Katsanis and **N. Larmonier.** Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; **Cancer Research 2013;73 (8 Suppl):Abstract nr 4740**. doi:10.1158/1538-7445.AM2013-4740

D.Alizadeh, E. Katsanis, **N. Larmonier**. Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; **Cancer Research 2014;74(19 Suppl):Abstract nr 150**. doi:10.1158/1538-7445.AM2014-150

♦ Other scientific communications

N. Larmonier, A. Nicolas, F. Ghiringhelli, D. Cathelin, F. Martin and B. Bonnotte. *Effects of progressive and regressive tumor cells on bone marrow derived dendritic cell phenotype.* Annual congress on Dendritic Cells (CFCD), Pasteur Institute, Paris, France. *Poster, 2003.*

Y. Zeng**,** X. Cai, **N. Larmonier**, E. Katsanis. *Chaperon Rich Cell Lysates (CRCL) activates innate immune response.* Keystone symposia 2005, Inflammation and Cancer. Keystone, Colorado, USA. *Poster, 2005.*

N. Larmonier, Y. Zeng, M. Marron, S. Thompson, E. Katsanis. *Role of $CD4^+CD25^+$ regulatory T cells in the immune response to Chaperone Rich Cell Lysates (CRCL) –based vaccination against a $BCR\text{-}ABL^+$ leukemia.* Keystone symposia 2005, Basic aspects of Tumor Immunology. Keystone, Colorado, USA. *Poster, 2005.*

N. Larmonier, Y. Zeng, S. Andreansky, M. Marron, J. Cantrell, E. Katsanis. *Tumor-derived $CD4^+CD25^+$ regulatory T cells suppress dendritic cell function by a TGF-b and IL-10 dependent mechanism.* Frontiers in Biomedical Research 2005, University of Arizona Health Sciences Center, Tucson, Arizona, USA. *Poster, 2005.*

N. Larmonier, Y. Zeng, S. Andreansky, M. Marron, J. Cantrell, E. Katsanis. *Tumor-derived $CD4^+CD25^+$ regulatory T cells suppression of dendritic cell function involves TGF-b and IL-10.* Frontiers in Immunobiology and Immunopathogenesis Symposium 2006, University of Arizona Health Sciences Center, Tucson, Arizona, USA. *Poster, 2006.*

J. Cantrell, X. Cai, Y. Zeng, **N. Larmonier**, E. Katsanis. *Adjuvant Effect of CRCL: Activation of dendritic cells and macrophages*. Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, *Poster, 2006.*

N. Larmonier, J. Cantrell, E. Katsanis. *Modulation of regulatory T lymphocyte-induced suppression of antigen presenting cells by chaperone rich cell lysates*. American Association for Cancer Research Special Conference, Tumor Immunology: an integrated perspective, Miami, Florida, *Poster, 2006.*

C.B. Larmonier, J.K. Uno, M.A. Lipko, **N. Larmonier**, F. Ghishan, P.R. Kiela. *Protective Effects of Dietary Curcumin in Trinitrobenzene Sulfonic Acid (TNBS)-Induced Colitis are Mouse Strain-Dependent*. Digestive Disease Week, Washington, D.C., Poster, 2007.

C.J. LaCasse, N. Janikashvili1, J. Cantrell, E. Situ, **N. Larmonier** and E. Katsanis. *Suppression of $CD4^+CD25^+$ regulatory T cells by imatinib mesylate*. Third Frontiers in Immunobiology and Immunopathogenesis Symposium 2008, University of Arizona Health Sciences Center, Tucson, Arizona, USA. *Poster, 2008.*

J. Cantrell, **N. Larmonier** and E. Katsanis. *Adjuvant effects of CRCL: CRCL activation of DC and Macrophages.* Third Frontiers in Immunobiology and Immunopathogenesis Symposium 2008, University of Arizona Health Sciences Center, Tucson, Arizona, USA. *Poster, 2008.*

E. Situ, D. Mérino, N. Janikashvili, E. Katsanis and **N. Larmonier**. *Evaluation of Tumor Necrosis Factor -Related Apoptosis-Inducing Ligand (TRAIL) effects on regulatory T cells.* Third Frontiers in Immunobiology and Immunopathogenesis Symposium 2008, University of Arizona Health Sciences Center, Tucson, Arizona, USA. *Poster, 2008.*

J. Fraszczak, M. Trad, E. Katsanis, B. Bonnotte and **N. Larmonier**. *Dendritic cells activated with a TLR-4 agonist kill tumor cells by a peroxynitrite-dependent mechanism and present antigens to specific T lymphocytes.* Frontiers in Biomedical Research 2008, College of Medicine, University of Arizona, Tucson, Arizona, USA. *Poster, 10/2008.*

J. Fraszczak, M. Trad, C. Dominique, N. Janikashvili, E. Katsanis, B. Bonnotte and **N. Larmonier.** *Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.* Club Francophone des Cellules Dendritiques, Paris, France. *Oral communication (J. Fraszczak), 03/2009.*

J. Fraszczak, Amanda Herrell, Nona Janikashvili, M. Trad, E. Katsanis, B. Bonnotte and **N. Larmonier.** *Cytotoxic dendritic cells as negative regulators of Treg.* Fourth Frontiers in Immunobiology and Immunopathogenesis Symposium, Tucson, Arizona. *Poster, 03/2009.*

M. Trad, E. Katsanis, B. Bonnotte and **N. Larmonier**. *Tumor-infiltrating $CD11c^+$ dendritic cells suppress T cell activation.* Frontiers in Biomedical Research 2009, College of Medicine, University of Arizona, Tucson, Arizona. *Poster, 10/2009.*

C. LaCasse, N. Janikashvili, E. Katsanis and **N. Larmonier**. *Th-1 Lymphocytes Promote Dendritic Cell Tumoricidal Activity*. American Association for Cancer Research, Special Conference: Tumor Immunology: Basic and Clinical Advances. Miami, Florida. 2010. *Poster and Selected for Oral Presentation.*

L. Amini, N. Hanke, E. Katsanis, and **N. Larmonier**. *Differential regulation of iNOS-dependent tumor cell killing by dendritic cells generated with IL-4 or IL-15*. Twenty-Second Annual Undergraduate Biology Research Conference, Tucson, Arizona. *Poster, 01/2011.*

N. Hanke, C. LaCasse, E. Katsanis and **N. Larmonier**. *Differential regulation of the tumor killing activity of IL-4 and IL-15 DC*. Frontiers in Biomedical Research 2011, College of Medicine, University of Arizona, Tucson, Arizona. *Poster, 11/2011.*

N. Hanke, C. LaCasse, E. Katsanis and **N. Larmonier.** *Regulation of iNOS-dependent cytotoxic activity of dendritic cells.* Seventh Annual Frontiers in Immunobiology and Immunopathogenesis Symposium. *Poster and oral presentation, 03/2012.*

D. Alizadeh, C. Larmonier, Neale T Hanke, C.LaCasse, A. Lorentz, E. Katsanis and **N. Larmonier.** *T helper-17 Lymphocytes impair melanoma development.* Seventh Annual Frontiers in Immunobiology and Immunopathogenesis Symposium. *Poster, 03/2012.*

E. Nieblas, C. LaCasse, E. Katsanis and **N. Larmonier.** *Characterization of the CD4+ T helper-1 lymphocyte population used in the therapy of A20 Lymphoma in mice.* 17th Annual University of Arizona Graduate College Undergraduate Research Opportunities Consortium (UROC) Conference. *Poster and Oral Presentation, 8/2012*

M.F. Acosta, E. Nieblas, C. LaCasse, E. Katsanis and **N. Larmonier.** *Generation of inducible T regulatory lymphocytes in different conditions in vitro.* 17th Annual University of Arizona Graduate College Undergraduate Research Opportunities Consortium (UROC) Conference. *Poster and Oral Presentation, 8/2012*

N. Janikashvili, C. LaCasse, N. Hanke, A. Gautheron, M. Trad, M. Ciudad, E. Katsanis, B. Bonnotte and **N. Larmonier.** *IFN-γ promotes mouse bone-marrow dendritic cell cytotoxic function through STAT-1*. Annual congress on Dendritic Cells (CFCD), Pasteur Institute, Paris, France. *Poster, 12/2012.*

M. Trad, N. Janikashvili, J. Fraszczak, Claire Larmonier, Collin LaCasse, Darya Alizadeh, Sara Centuori, F. Bonnefoy, S. Perruche, E. Katsanis, **N. Larmonier*** and B. Bonnotte*. *Immunosuppressive function of tumor-inflitrating dendritic cells*

mediated by ectonucleotidase CD39. Annual congress on Dendritic Cells (CFCD), Pasteur Institute, Paris, France. *Poster, 12/2012* (* Equal Contribution).

D. Alizadeh, M. Trad, E. Katsanis and **N. Larmonier.** *Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model***.** American Association for Cancer Research Annual Meeting 2013. Washington, DC, USA. *Poster,* 4/2013.

D. Alizadeh, E. Katsanis and **N. Larmonier.** *Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells***.** American Association for Cancer Research Annual Meeting 2014. San Diego, CA, USA. *Poster,* 4/2014.

Invited Speaker

Tumoricidal activity of freshly isolated bone marrow cells. Scientific Conference of the Medicine and Pharmacy Faculties, Dijon, France. 10/2002.

Immunity versus tolerance in cancer. Department of Pediatrics Research Seminars, University of Arizona, Tucson, Arizona. 09/2004.

$CD4^+CD25^+$ Regulatory T cells: Obstacles in dendritic cell-based cancer immunotherapy? Department of Immunology Seminar Series, Immunobiology Graduate Program, University of Arizona, Tucson, Arizona. 09/2005.

The immunosuppressive lymphocyte: Dr. Jekyll or Mr. Hyde? Department of Pediatrics Research Seminars, University of Arizona, Tucson, Arizona. 10/2007.

Regulatory T lymphocytes in cancer: Myth or Reality? Department of Immunology Seminar Series, Immunobiology Graduate Program, University of Arizona, Tucson, Arizona. 10/2007.

Regulatory T lymphocytes in cancer: when Dr Jekyll turns into Mr Hyde, can imatinib mesylate come to the rescue? Third Frontiers in Immunobiology and Immunopathogenesis Symposium, Hilton El Conquistador, Oro Valley, Arizona. 03/2008.

The immune system: what it is and how it can be driven to fight cancer? Conference, AmeriSchools High School, Tucson, Arizona. 04/2008.

The regulatory (suppressor) T lymphocyte in cancer: when Dr. Jekyll turns into Mr. Hyde… Cancer Biology Graduate Interdisciplinary Program Seminar Series, Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona. 09/2008.

Cytotoxic dendritic cells as negative regulators of Treg. Fourth Frontiers in Immunobiology and Immunopathogenesis Symposium, Tucson, Arizona. 03/2009.

Combination approaches for cancer immunotherapy. University of Burgundy and Franche-Comté, INSERM UMR1098, Besancon, France. 12/10/2012.

Exploiting the qualities of chemotherapeutic agents to entice oncologists to reconsider immune therapies. Collaborative Cancer Grand Rounds, Arizona Cancer Center, Tucson, AZ. 3/1/2013.

Targeting immunosuppressive cells and chemoimmunotherapeutic approaches for cancer. Joseph Fourier University, Institut Albert Bonniot, Grenoble, France. 5/14/2013.

Chemotherapeutic agents and immune-based therapies: unexpected allies against cancer. Department of Basic Medical Sciences, Phoenix, AZ. 5/1/2014.

Research grants and funding

Active

ARC	Th9 and Th17 lymphocytes in cancer: plasticity and therapeutic potential.	2015-2017	50 000 €	Porteur du projet
Ligue Contre le Cancer	Therapeutic potential of Th9 and Th17 in cancer and interaction with suppressive myeloid cells	2016	15 000 €	Porteur du projet
Ligue Contre le Cancer	Equipe Labélisée Ligue	2016	400 000 €	Porteur : Dechanet-Mervile

Exécutés

Agence	Titre	Période	Montant	Rôle
National Institute of Health. NCI RO1	Immunotherapy for CML	2009-2015	$ 1 250 000	Co-Investigateur (60% effort)
University of Arizona. Hem/Onc Section	Institutional Funding	2006-2015	$ 200 000	Investigateur Principal
National Institute of Health. NHLBI RO1	Blocking Hypertension by regulatory T cells	2009-2014	$ 1 250 000	Collaborator (5% effort) PI : Larson
Alex's Lemonade Stand Foundation for Childhood Cancer #432160	Reciprocal interactions between tumor killer DC and tumor-induced Treg	2008-2010	$ 80 000	Investigateur Principal
Institutional Cancer Research Grant. ACS IRG7400131	Regulatory T cells in colon carcinogenesis: Role and modulation with curcumin	2008-2009	$ 30 000	Investigateur Principal
Leukemia and Lymphoma Society 5188-07	Career Development Fellow Award. Modulation of regulatory T cell activity by Chaperone Rich Cell Lysate	2006-2009	$ 150 000	Investigateur Principal